Skip to Content

Tandem Diabetes Care Inc

TNDM: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$25.00KrkwCmvdpsnk

Heightened Competition and New Product Introductions Weigh on Tandem Diabetes' Growth

Business Strategy and Outlook

Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy path between the initial 2012 launch of its original t:slim pump and consistent positive earnings, Tandem still has a few years to go, from our perspective.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of TNDM so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center